PMU19 FIRST LINE TREATMENT WITH NATALIZUMAB REDUCES HEALTHCARE RESOURCE USE AND IMPAIRMENT OF WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) PATIENTS COMPARED TO NATALIZUMAB DELAYED USE